January 10, 2011 | BIND Biosciences has started the Phase 1 trial for the first candidate from its broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel. In preclinical cancer models, BIND-014 was shown to deliver up to 20 times more docetaxel to the tumor site than an equivalent dose of Taxotere.  The increased accumulation of docetaxel at the site of disease in preclinical systems translated to marked improvements in antitumor activity and tolerability. BIND